Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares RepurchasedShort-Term Debt repayments
Ratios

Nutex Health (NUTX) EBIAT (2016 - 2025)

Nutex Health's EBIAT history spans 16 years, with the latest figure at $16.6 million for Q4 2025.

  • For Q4 2025, EBIAT fell 83.31% year-over-year to $16.6 million; the TTM value through Dec 2025 reached $180.4 million, up 90.24%, while the annual FY2025 figure was $180.4 million, 90.24% up from the prior year.
  • EBIAT for Q4 2025 was $16.6 million at Nutex Health, down from $96.8 million in the prior quarter.
  • Across five years, EBIAT topped out at $99.5 million in Q4 2024 and bottomed at -$422.9 million in Q3 2022.
  • The 5-year median for EBIAT is -$2.3 million (2021), against an average of -$10.1 million.
  • The largest annual shift saw EBIAT plummeted 23369.3% in 2022 before it surged 9473.8% in 2025.
  • A 5-year view of EBIAT shows it stood at $13.5 million in 2021, then tumbled by 179.1% to -$10.7 million in 2022, then tumbled by 196.64% to -$31.6 million in 2023, then skyrocketed by 414.71% to $99.5 million in 2024, then tumbled by 83.31% to $16.6 million in 2025.
  • Per Business Quant, the three most recent readings for NUTX's EBIAT are $16.6 million (Q4 2025), $96.8 million (Q3 2025), and $16.1 million (Q2 2025).